{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:08:11Z","timestamp":1784092091148,"version":"3.55.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560966"],"award-info":[{"award-number":["82560966"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bupleurum-containing formulas are widely used in China as adjunct to chemotherapy for triple-negative breast cancer (TNBC). However, systematic evidence on their efficacy and safety remains limited. This study evaluates the clinical effects and safety of Bupleurum-containing formulas combined with chemotherapy in the patients with TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched seven electronic databases (PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Sinomed, VIP Database, and Wanfang Database) from inception to January 31, 2026. Studies meeting predefined inclusion criteria were identified through a systematic search. Two researchers independently conducted study selection, data extraction, and risk of bias assessment to ensure accuracy and reduce potential bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with chemotherapy alone, Bupleurum-containing traditional Chinese medicine (TCM) formulas combined with chemotherapy improved several clinical outcomes in patients with TNBC. The combined treatment significantly increased the objective response rate (ORR) (RR\u00a0=\u00a01.32, 95% CI: 1.18\u20131.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.00001) and disease control rate (DCR) (RR\u00a0=\u00a01.15, 95% CI: 1.09\u20131.21,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.00001), and improved quality of life (QOL) (MD\u00a0=\u00a06.48, 95% CI: 4.93\u20138.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.00001). It was also associated with changes in peripheral blood CD3\n                      <jats:sup>+<\/jats:sup>\n                      , CD4\n                      <jats:sup>+<\/jats:sup>\n                      , CD8\n                      <jats:sup>+<\/jats:sup>\n                      T lymphocytes, as well as the CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      ratio. Subgroup analysis indicated that interventions lasting \u226512 weeks was associated with greater improvements in ORR. In terms of safety, the combined regimen reduced the incidence of grade III-IV gastrointestinal adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combining Bupleurum-containing TCM formulas with chemotherapy shows potential in improving ORR, DCR, and QOL, while reducing treatment-related toxicity in patients with TNBC. This approach may serve as an adjunctive strategy, but these findings should be interpreted with caution, and further high-quality studies are needed.<\/jats:p>\n                    <jats:p>This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was prospectively registered in the PROSPERO database (registration number: CRD420251269445).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251269445.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1867349","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:44:35Z","timestamp":1784090675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shangshang","family":"Li","sequence":"first","affiliation":[{"name":"Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Traditional Chinese Medicine Rehabilitation Department, Guihang Pingba Hospital","place":["Anshun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhu","family":"Ke","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Hubei University of Chinese Medicine","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiu","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Oncology, GuiHang Guiyang Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglai","family":"Cui","sequence":"additional","affiliation":[{"name":"Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"He","sequence":"additional","affiliation":[{"name":"Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, GuiHang Guiyang Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[{"name":"Hospital Office of the President, Guihang Guiyang Hospital","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7554","article-title":"Role of immunotherapy in triple-negative breast cancer","volume":"18","author":"Keenan","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X21500737","article-title":"Efficacy and safety of Chinese herbal medicine on treatment of breast cancer: a meta-analysis of randomized controlled trials","volume":"49","author":"Ho","year":"2021","journal-title":"Am J Chin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1614903","article-title":"A systematic review and exploration of clinical application of liver depression syndrome in breast cancer","volume":"15","author":"Wu","year":"2025","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3892\/ol.2025.14912","article-title":"Role, mechanisms and effects of Radix Bupleuri in anti-breast cancer (Review)","volume":"29","author":"Jiang","year":"2025","journal-title":"Oncol Lett"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.09.038","article-title":"Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting \u03b2-catenin signaling","volume":"108","author":"Wang","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01487","article-title":"Saikosaponin A inhibits triple-negative breast cancer growth and metastasis through downregulation of CXCR4","volume":"9","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2017.01.022","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7\/adriamycin cells","volume":"213","author":"Li","year":"2017","journal-title":"Pathol Res Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.16367\/j.issn.1003-5028.2015.09.0928","article-title":"Thirty cases with triple negative breast cancer prevented and treated by the method of soothing the liver, strengthening the spleen, removing toxicity and eliminating stagnation","volume":"35","author":"Cui","year":"2015","journal-title":"Henan Traditional Chin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.19621\/j.cnki.11-3555\/r.2021.1430","article-title":"Clinical observation of Cigu Pingyan Decoction in treating stage II and III triple-negative breast cancer","volume":"29","author":"He","year":"2021","journal-title":"China's Naturopathy"},{"key":"B21","article-title":"Long-term efficacy of Shugan Yishen Formula in treating triple-negative breast cancer and its effect on Karnofsky score","volume":"7","author":"Jiang","year":"2022","journal-title":"Doctor"},{"key":"B22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.19335\/j.cnki.2096-1219.2021.15.045","article-title":"Effect analysis of Soothing Liver and Strengthening Spleen Decoction combined with GP chemotherapy for advanced triple negative breast cancer","volume":"7","author":"Ju","year":"2021","journal-title":"Smart Healthcare"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-7171.2019.02.054","article-title":"Effect of regulating spleen and soothing liver method combined with chemotherapy on efficacy and immune function in patients with triple-negative breast cancer","volume":"36","author":"Li","year":"2019","journal-title":"J Clin Res"},{"key":"B24","volume-title":"Clinical observation of harmonizing liver-spleen treating advanced triple-negative breast cancer with liver-qi stagnation and phlegm stagnation type","author":"Li","year":"2014"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.13194\/j.issn.1673-842x.2016.10.056","article-title":"Clinical efficacy of chemotherapy combined with traditional Chinese medicine for promoting the circulation of qi and invigorating spleen in the treatment of metastatic triple negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"J Liaoning Univ Traditional Chin Med"},{"key":"B26","article-title":"Clinical observation of Shuganjieyu Decoction in the treatment of three negative breast cancer","volume":"47","author":"Liu","year":"2025","journal-title":"Hubei J TCM"},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.13455\/j.cnki.cjcor.2017.08.01","article-title":"Efficacy of Fuzheng Hualiu decoction combined with gemcitabine and cisplatin for metastatic triple negative breast cancer","volume":"24","author":"Mao","year":"2017","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"B28","article-title":"Clinical analysis of traditional Chinese medicine combined with chemotherapy in the treatment of metastatic triple-negative breast cancer","volume":"32","author":"Ren","year":"2016","journal-title":"J Pract Traditional Chin Med"},{"key":"B29","volume-title":"Clinical study of Shugan Huazheng Capsule combined with chemotherapy for treating breast cancer of qi stagnation and phlegm coagulation type","author":"Song","year":"2018"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.16295\/j.cnki.0257-358x.2022.06.009","article-title":"Effect of Shugan Liqi Xiaoyan Formula combined with chemotherapy on advanced three negative breast cancer","volume":"41","author":"Tian","year":"2022","journal-title":"Shandong J Traditional Chin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.13935\/j.cnki.sjzx.200534","article-title":"Clinical observation of Shugan Jianpi Decoction combined with chemotherapy in the treatment of advanced breast cancer","volume":"15","author":"Wang","year":"2020","journal-title":"World J Integrated Traditional Western Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-9572.2015.06.05","article-title":"Clinical efficacy and safety of combined chemotherapy with traditional Chinese medicine for smoothing liver, invigorating spleen and tonifying kidney in the treatment of metastatic triple negative breast cancer with liver stagnation","volume":"18","author":"Wang","year":"2015","journal-title":"Chin Gen Pract"},{"key":"B33","article-title":"Effect analysis of Shugan Jianpi Yishen Decoction combined with chemotherapy in the treatment of metastatic triple-negative breast cancer","author":"Wang","year":"2022","journal-title":"Care Health"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.19288\/j.cnki.issn.1000-2723.2018.01.010","article-title":"Effect of Shugan Jianpi Yishen method on T cell subsets and prognosis of metastatic triple-negative breast cancer with liver stagnation type","volume":"41","author":"Wu","year":"2018","journal-title":"J Yunnan Univ Chin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3969\/j.issn.1009-6019.2016.06.240","article-title":"Observation on curative effect of Pingyu Shiru Formula combined with chemotherapy in the treatment of postoperative triple-negative breast cancer","volume":"10","author":"Zhang","year":"2016","journal-title":"For all Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.16305\/j.1007-1334.2018.09.012","article-title":"Clinical observation of Tiaopi Shugan Yishen Decoction combined with chemotherapy in the treatment of postoperative recurrence of triple-negative breast cancer","volume":"52","author":"Zhang","year":"2018","journal-title":"Shanghai J Traditional Chin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.14163\/j.cnki.11-5547\/r.2015.33.129","article-title":"Effect analysis of Shugan Jianpi Yishen traditional Chinese medicine combined with chemotherapy in the treatment of metastatic triple-negative breast cancer with liver stagnation type","volume":"10","author":"Zhang","year":"2015","journal-title":"China Pract Med"},{"key":"B38","volume-title":"Clinical observation of Xiaoyao Loubei prescription combined with neoadjuvant chemotherapy in treating triple-negative breast cancer with liver depression and phlegm coagulation syndrome","author":"Zhang","year":"2022"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1005-1457.2020.01.039","article-title":"Analysis of clinical value of Shugan Jianpi Yishen Decoction combined with chemotherapy in the treatment of metastatic triple-negative breast cancer","volume":"28","author":"Zhao","year":"2020","journal-title":"Sichuan J Anat"},{"key":"B40","article-title":"Effect of self-made Shugan Jianpi Jiangni Recipe on occurrence of toxic and side effects for patients with triple-negative breast cancer by TEC chemotherapy","volume":"39","author":"Zhao","year":"2021","journal-title":"J Sichuan Traditional Chin Med"},{"key":"B41","volume-title":"The clinical study of combining Xiaoyao Powder and Xeloda on treating advanced triple negative breast cancer","author":"Zhu","year":"2014"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: an analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"B45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"B46","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1142\/S0192415X2450040X","article-title":"A review of traditional Chinese medicine for triple negative breast cancer and the pharmacological mechanisms","volume":"52","author":"Wu","year":"2024","journal-title":"Am J Chin Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032350","article-title":"Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors","volume":"101","author":"Zhang","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1125373","article-title":"Impact of traditional East Asian medicine as an add-on therapy on survival and recurrence after surgery for breast cancer: a systematic review and meta-analysis","volume":"14","author":"Yoon","year":"2023","journal-title":"Front Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20202509","article-title":"Traditional Chinese biomedical preparation (Huaier Granule) for breast cancer: a PRISMA-compliant meta-analysis","volume":"40","author":"Yao","year":"2020","journal-title":"Biosci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2010.01170.x","article-title":"Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action","volume":"63","author":"Ashour","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.050057","article-title":"Astragalus polysaccharide enhances the therapeutic efficacy of cisplatin in triple-negative breast cancer through multiple mechanisms","volume":"33","author":"Sun","year":"2025","journal-title":"Oncol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.05.120","article-title":"Radix Astragali polysaccharide RAP directly protects hematopoietic stem cells from chemotherapy-induced myelosuppression by increasing FOS expression","volume":"183","author":"Bao","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-025-05371-5","article-title":"Saikosaponin D modulates STAT3 and c-Myc expression in MDA-MB-231 cells: A comprehensive in silico and in vitro study","volume":"197","author":"Deivendran","year":"2025","journal-title":"Appl Biochem Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11155","article-title":"Saikosaponin D inhibits autophagosome-lysosome fusion and induces autophagy-independent apoptosis in MDA-MB-231 breast cancer cells","volume":"22","author":"Fu","year":"2020","journal-title":"Mol Med Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155945","article-title":"Saikosaponin D potentiates the antineoplastic effects of doxorubicin in drug-resistant breast cancer through perturbing NQO1-mediated intracellular redox balance","volume":"133","author":"Luo","year":"2024","journal-title":"Phytomedicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/745295","article-title":"Saikosaponin-d enhances the anticancer potency of TNF-\u03b1 via overcoming its undesirable response of activating NF-Kappa B signalling in cancer cells","volume":"2013","author":"Wong","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1532579","article-title":"Saikosaponin A induces cellular senescence in triple-negative breast cancer by inhibiting the PI3K\/Akt signalling pathway","volume":"16","author":"Wu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.214114","article-title":"Targeted delivery of Saikosaponin A and doxorubicin via hyaluronic acid-modified ZIF-8 nanoparticles for TNBC treatment: Inhibiting metastasis and reducing cardiotoxicity","volume":"167","author":"Li","year":"2025","journal-title":"Biomater Adv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2016.10.112","article-title":"Anti-tumor and immunomodulatory activities induced by an alkali-extracted polysaccharide BCAP-1 from Bupleurum chinense via NF-\u03baB signaling pathway","volume":"95","author":"Song","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/13880209.2021.1992448","article-title":"Saikosaponin D: review on the antitumour effects, toxicity and pharmacokinetics","volume":"59","author":"Zhou","year":"2021","journal-title":"Pharm Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/13880209.2023.2166966","article-title":"Chaihu Shugan San promotes gastric motility in rats with functional dyspepsia by regulating Drp-1-mediated ICC mitophagy","volume":"61","author":"Li","year":"2023","journal-title":"Pharm Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psychooncology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12916-024-03638-y","article-title":"Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers","volume":"22","author":"Lee","year":"2024","journal-title":"BMC Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature25973","article-title":"Environment dominates over host genetics in shaping human gut microbiota","volume":"555","author":"Rothschild","year":"2018","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.02.024","article-title":"Gut microbiota, a new frontier to understand traditional Chinese medicines","volume":"142","author":"Feng","year":"2019","journal-title":"Pharmacol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1867349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:45:04Z","timestamp":1784090704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1867349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":67,"alternative-id":["10.3389\/fonc.2026.1867349"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1867349","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1867349"}}